表紙
市場調査レポート

慢性リンパ性白血病治療薬の世界市場:2015-2019年

Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 336913
出版日 ページ情報 英文 87 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
慢性リンパ性白血病治療薬の世界市場:2015-2019年 Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019
出版日: 2015年08月05日 ページ情報: 英文 87 Pages
概要

慢性リンパ性白血病はリンパ球が過剰に増殖する悪性疾患であり、まずBリンパ球に障害を起こした後に体内の他部分に広がる恐れがあることが明らかにされています。白血病はがん細胞の形成が遅いことから、その多くが進行の後期に発見されます。進行期には悪性腫瘍が脾臓や肝臓、リンパ節に広がりますが、進行は一律でないため、予見は困難です。症状はリンパ節の腫れ、疲労感、発熱、感染症、肋骨下の痛み、体重の減少など。治療には放射線、ステロイド、化学療法、標的治療、移植 (骨髄や幹細胞) 、脾臓摘出手術などが用いられます。慢性リンパ性白血病治療薬の世界市場は今後今後2019年までの間、18.52%の複合年間成長率で拡大する見込みです。

当レポートでは、慢性リンパ性白血病治療薬の世界市場に注目し、2015-2019年の期間を対象に、その概況および需給規模の推移を考察・予測するほか、市場発展への動向、推進要因、課題、主要企業プロファイルなど最新の分析情報をまとめています。

第1章 エグゼクティブサマリー

第2章 略語一覧

第3章 レポートの範囲

  • 市場概要
  • 製品構成

第4章 製品プロファイル

  • Gazyva/Gazyvaro
  • MabThera/Rituxan
  • Arzerra
  • Treanda

第5章 市場調査方法

  • 市場調査プロセス
  • 取材方法

第6章 疾患の概要

  • 疾患の理解
  • 慢性リンパ性白血病の種類
  • 症状
  • 進行段階
  • 疫学
  • 管理
  • 経済的負担

第7章 イントロダクション

第8章 市場環境

  • 市場概要
  • 市場規模および予測
  • ファイブフォース分析

第9章 開発パイプラインポートフォリオ

  • 代表的パイプライン分子についての重要情報
    • RG 105 SC剤形
    • Obinutuzumab/ Venetoclax
    • RG 7596 (Polatuzumab vedotin)
    • RG 7601 (Venetoclax)

第10章 市場セグメンテーション - 投与経路別

  • 経口投与
  • 非経口投与

第11章 市場セグメンテーション - 分子形態別

  • 小分子
  • 生物製剤

第12章 市場セグメンテーション - 地域別

第13章 選定基準

第14章 市場成長推進要因

第15章 推進要因とその影響度

第16章 市場課題

第17章 推進要因と課題の影響度

第18章 市場動向

第19章 動向とその影響度

第20章 事業環境

  • 競合状況
    • 重要情報
    • M&A
  • 市場シェア分析:2014年
    • F. Hoffmann-La Roche
    • Teva Pharmaceutical Industries
    • Novartis
  • その他の有望企業

第21章 主要供給企業分析 (重要ファクト、事業概要、事業・地域別売上、事業戦略、重要情報、SWOT分析など)

  • F. Hoffmann-La Roche
  • Novartis
  • Teva Pharmaceutical Industries

第22章 シリーズ内の関連レポート

目次
Product Code: IRTNTR6598

About Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia is a malignant condition characterized by increased production of lymphocytes. It has been observed that the cancer first affects B-lymphocytes and then it can spread to other parts of the body. This leukemia is diagnosed mostly at later stages because of the slow buildup of the cancerous cells. During the course of the disease, the malignancy spreads to the spleen, liver, and lymph nodes. The course of the disease is heterogeneous, and prognosis is difficult. Symptoms include swelling of the lymph nodes, fatigue, fever, infection, pain beneath the ribs, and weight loss. Chronic lymphocytic leukemia can be treated with radiation, steroids, chemotherapy, targeted therapy, transplants (bone marrow, stem cell), and surgical procedure to remove the spleen (splenectomy).

Technavio's analysts forecast the global chronic lymphocytic leukemia therapeutics market to grow at a CAGR of 18.52% over the period 2014-2019.

Covered in this Report

In this report, Technavio covers the present scenario and growth prospects of the global chronic lymphocytic leukemia therapeutics market for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of various drugs used in the treatment of chronic lymphocytic leukemia.

Based on the type of molecule, we group the market into two categories:

  • Biologics
  • Small molecules

Based on the route of administration, we group the market into two:

  • Oral
  • Parenteral

This report includes a discussion of the market in the following three regions:

  • Americas: The major countries focused in the Americas are the US, Canada, Mexico, and Brazil
  • EMEA: The major countries in this region are the UK, Germany, Italy, France, Spain and Middle
  • Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
  • APAC: The major countries in this region are Japan, China, Australia, Singapore, South Korea, and India. APAC is a major untapped market with many leading vendors in the global chronic lymphocytic leukemia therapeutics market.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. In addition, it discusses the major drivers and challenges, as well as the key trends.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • F. Hoffmann-La Roche
  • Novartis
  • Teva Pharmaceutical Industries

Other Prominent Vendors

  • Actavis
  • Amgen
  • Aryogen
  • Astellas
  • Bristol-Myers Squibb
  • Eagle Pharmaceuticals
  • Eisai
  • Fresenius Kabi
  • Genmab
  • Gilead Sciences
  • H. Lundbeck
  • Hospira
  • idd biotech
  • Immunomedics
  • Johnson & Johnson
  • Mundipharma
  • Mylan
  • Noxxon
  • Ono Pharmaceutical
  • PDL BioPharma
  • Pfizer
  • Pharmacyclics
  • Regeneron
  • Sagent Pharmaceutical
  • Sanofi
  • SymBio Pharmaceuticals
  • TheraMAB

Key Market Driver

  • Increase in Patient Pool
  • For a full, detailed list, view our report

Key Market Challenge

  • Unknown Disease Etiology
  • For a full, detailed list, view our report

Key Market Trend

  • Strategic Alliances
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

    • 04.1.1. Gazyva/Gazyvaro
    • 04.1.2. MabThera/Rituxan
    • 04.1.3. Arzerra
    • 04.1.4. Treanda

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Disease Overview

  • 06.1. Understanding the Disease
  • 06.2. Types of Chronic Lymphocytic Leukemia
  • 06.3. Symptoms
  • 06.4. Diagnosis
  • 06.5. Staging
  • 06.6. Epidemiology
  • 06.7. Management
  • 06.8. Economic Burden

07. Introduction

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. Five Forces Analysis

09. Pipeline Portfolio

  • 09.1. Key Information on the Major Pipeline Molecules
    • 09.1.1. RG 105 SC Formulation
    • 09.1.2. Obinutuzumab/ Venetoclax
    • 09.1.3. RG 7596 (Polatuzumab vedotin)
    • 09.1.4. RG 7601 (Venetoclax)

10. Market Segmentation by Route of Administration

  • 10.1. Oral
  • 10.2. Parenteral

11. Market Segmentation by Type of Molecule

  • 11.1. Small Molecules
  • 11.2. Biologics

12. Geographical Segmentation

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

  • 20.1. Competitive Scenario
    • 20.1.1. Key News
    • 20.1.2. Mergers and Acquisitions
  • 20.2. Market Share Analysis 2014
    • 20.2.1. F. Hoffmann-La Roche
    • 20.2.2. Teva Pharmaceutical Industries
    • 20.2.3. Novartis
  • 20.3. Other and Future Prominent Vendors

21. Key Vendor Analysis

  • 21.1. F. Hoffmann-La Roche
    • 21.1.1. Key Facts
    • 21.1.2. Business Overview
    • 21.1.3. Business Segmentation
    • 21.1.4. Business Segmentation by Revenue 2012 and 2013
    • 21.1.5. Sales by Geography
    • 21.1.6. Business Strategy
    • 21.1.7. Key Information
    • 21.1.8. SWOT Analysis
  • 21.2. Novartis
    • 21.2.1. Key Facts
    • 21.2.2. Business Description
    • 21.2.3. Business Segmentation
    • 21.2.4. Revenue by Business Segmentation
    • 21.2.5. Revenue Comparison 2012 and 2013
    • 21.2.6. Sales by Geography
    • 21.2.7. Business Strategy
    • 21.2.8. Key Developments
    • 21.2.9. SWOT Analysis
  • 21.3. Teva Pharmaceutical Industries
    • 21.3.1. Key Facts
    • 21.3.2. Business Overview
    • 21.3.3. Business Segmentation
    • 21.3.4. Revenue by Business Segmentation
    • 21.3.5. Revenue Comparison 2012 and 2013
    • 21.3.6. Revenue Segmentation by Geography
    • 21.3.7. Business Strategy
    • 21.3.8. Key Developments
    • 21.3.9. SWOT Analysis

22. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Snapshot of Chronic Lymphocytic Leukemia
  • Exhibit 3: Type of Chronic Lymphocytic Leukemia
  • Exhibit 4: Major Diagnostic Procedures to Determine Chronic Lymphocytic Leukemia
  • Exhibit 5: Other Diagnostic Procedures to Determine Chronic Lymphocytic Leukemia
  • Exhibit 6: Rai Staging of Chronic Lymphocytic Leukemia
  • Exhibit 7: Binet Staging of Chronic Lymphocytic Leukemia
  • Exhibit 8: Management of Chronic Lymphocytic Leukemia
  • Exhibit 9: Economic Burden of Chronic Lymphocytic Leukemia
  • Exhibit 10: Global Chronic Lymphocytic Leukemia Therapeutics Market 2014-2019 ($ millions)
  • Exhibit 11: Key Takeaways: Global Chronic Lymphocytic Leukemia Therapeutics Market
  • Exhibit 12: Drug Candidates by Stage of Development, in percentage
  • Exhibit 13: Segmentation of Global Chronic Lymphocytic Leukemia Therapeutics Market by Route of Administration
  • Exhibit 14: Segmentation of Global Chronic Lymphocytic Leukemia Therapeutics Market by Type of Molecules
  • Exhibit 15: Segmentation of Global Chronic Lymphocytic Leukemia Therapeutics Market by Geography, 2014
  • Exhibit 16: Drivers of Global Chronic Lymphocytic Leukemia Therapeutics Market
  • Exhibit 17: Challenges of Global Chronic Lymphocytic Leukemia Therapeutics Market
  • Exhibit 18: Trends of Global Chronic Lymphocytic Leukemia Therapeutics Market
  • Exhibit 19: Global Sales and YoY Growth Rate of Rituxan/MabThera 2010-2014 ($ millions)
  • Exhibit 20: Global Sales and YoY Growth Rate of Treanda 2010-2014 ($ millions)
  • Exhibit 21: Global Sales and YoY Growth Rate of Arzerra 2010-2014($ millions)
  • Exhibit 22: Sales and YoY Growth Rate of Arzerra in US 2010-2014 ($ millions)
  • Exhibit 23: Sales and YoY Growth Rate of Arzerra in Europe 2010-2014 ($ millions)
  • Exhibit 24: Region-wise Revenue Comparison of Arzerra 2010-2014 ($ millions)
  • Exhibit 25: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
  • Exhibit 26: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 27: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
  • Exhibit 28: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
  • Exhibit 29: Novartis AG: Business Segmentation
  • Exhibit 30: Novartis AG: Revenue by Business Segmentation 2013
  • Exhibit 31: Novartis AG: Revenue by Business Segmentation 2012 and 2013 ($ millions)
  • Exhibit 32: Novartis AG: Revenue by Geographical Segmentation 2013
  • Exhibit 33: Teva Pharmaceutical Industries Ltd.: Business Segmentation
  • Exhibit 34: Teva Pharmaceutical Industries Ltd.: Revenue by Business Segmentation 2013
  • Exhibit 35: Teva Pharmaceutical Industries Ltd.: Revenue by Business Segmentation 2012 and 2013 ($ millions)
  • Exhibit 36: Teva Pharmaceutical Industries Ltd.: Revenue by Geographical Segmentation 2013
Back to Top